Bacitracin

Summary

Bacitracin (CHEMBL1200558) is an approved protein antibacterial agent (ATC D06AX05); indicated across 8 conditions including pneumonia and burn.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: D06AX05 (+3 more)
• Indications: 8 conditions
• Clinical trials: 17
• Chemistry: 1422.7 Da · C66H103N17O16S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200558
Name	Bacitracin
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	10909430
ChEBI	CHEBI:35862
ATC	D06AX05, J01XX10, S01AA32, R02AB04
Molecular formula	C66H103N17O16S
Molecular weight	1422.7
InChIKey	CLKOFPXJLQSYAH-ABRJDSQDSA-N

SMILES: CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4

IUPAC name: (4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid

ChEBI definition: A homodetic cyclic peptide consisting of (4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carboxylic acid attached head-to-tail to L-leucyl,D-glutamyl, L-lysyl, D-ornityl, L-isoleucyl, D-phenylalanyl, L-histidyl. D-aspartyl and L-asparaginyl residues coupled in sequence and cyclised by condensation of the side-chain amino group of the L-lysyl residue with the C-terminal carboxylic acid group. It is the major component of bacitracin.

Pharmacological roles (ChEBI): antibacterial agent, antimicrobial agent.

Also known as: Albac 50, Baci-rx, Baciguent, Baciim, Bacilliquin, Bacitracin, Bacitracin component of lanabiotic, Bacitracin component of mycitracin, Bacitracin(non-injectable), sterile, Bacitracina, Bacitracine

Parent form; salt/anhydrous children: CHEMBL2096639

Patent coverage: 95 distinct patent families (154 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Epidermal growth factor receptor, Tyrosine-protein kinase Lck, 5-hydroxytryptamine receptor 1B, Undecaprenyl-diphosphatase.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P28564	5.87	Ki	1354	nM	CHEMBL_ACT_7599155
LCK	5.72	IC50	1923	nM	CHEMBL_ACT_7599146
P28564	5.53	IC50	2978	nM	CHEMBL_ACT_7599154
EGFR	5.27	IC50	5377	nM	CHEMBL_ACT_7599140
P60932	5.25	IC50	5600	nM	CHEMBL_ACT_18539459

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pneumonia	4	MONDO:0005249	EFO:0003106
burn	4	MONDO:0043519	EFO:0009516
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
paranasal sinus disorder	2	MONDO:0001735	EFO:0009481
osteomyelitis	0	MONDO:0005246	EFO:0003102

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE4	5
Not specified	4
PHASE2	3
PHASE3	2
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01350102	PHASE4	TERMINATED	The Relationship of Hemoglobin A1c and Diabetic Wound Healing
NCT01516463	PHASE4	WITHDRAWN	Using Santyl or Bacitracin on Second Degree Burns
NCT01668030	PHASE4	COMPLETED	Comparison of Wound Bed Establishment in Facial Burns
NCT02673229	PHASE4	TERMINATED	Comparison of Collagenase With Antibiotic Ointment of Minor Partial Thickness Burns
NCT03929224	PHASE4	COMPLETED	The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown
NCT00674999	PHASE2/PHASE3	WITHDRAWN	Use of Amnion on Partial Thickness Burns
NCT01002911	PHASE3	COMPLETED	Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)
NCT02809131	PHASE3	COMPLETED	Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
NCT00132600	PHASE2	COMPLETED	Clinical Evaluation of Bacitracin
NCT01222832	PHASE2	COMPLETED	Effectiveness of Antibiotic Delivery Via Bio-absorbable Sponge
NCT01359735	PHASE2	COMPLETED	Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
NCT00479193	PHASE1	WITHDRAWN	Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds
NCT03213249	PHASE1	COMPLETED	Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy
NCT07549828	Not specified	NOT_YET_RECRUITING	Sebum Metabolomics and Lipidomics for Clinical Applications
NCT00705354	Not specified	WITHDRAWN	Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following Endoscopic Sinus Surgery
NCT00997139	Not specified	COMPLETED	Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
NCT03968835	Not specified	WITHDRAWN	A Comparison of the Outcomes of Distal Fingertip Amputations Treated With Either Artificial (Xeroform) or Biological Dressings

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).